The FDA, Preemption, and the Supreme Court
| Autor: | Leonard H. Glantz, George J. Annas |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Device Approval
media_common.quotation_subject Preemption Legal history Industry Medicine Drug Approval health care economics and organizations Pharmaceutical industry media_common United States Food and Drug Administration business.industry Liability Doctrine Liability Legal General Medicine History 20th Century United States Supreme court Supreme Court Decisions Law Government Regulation business State Government |
| Zdroj: | New England Journal of Medicine. 358:1883-1885 |
| ISSN: | 1533-4406 0028-4793 |
| Popis: | Next fall, the Court will hear a case about preemption and FDA-approved drugs. The pharmaceutical industry is arguing that once the FDA approves a drug, the preemption doctrine implicitly deprives injured persons of the opportunity to prove it was inadequately labeled. Leonard Glantz and George Annas discuss the issue. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|